Company Performance Metrics
Phrontline Biopharma develops biopharmaceutical products to treat cancer through innovative antibody-drug conjugate technology. The company's innovation lies in engineering bispecific antibodies combined with a dual-payload platform, enabling simultaneous delivery of two cytotoxic agents. Its lead program, TJ101, is a bispecific ADC directed
at EGFR and B7-H3 for solid tumors; it has received IND clearance and has entered a Phase 1 clinical trial. Other pipeline assets (like TJ102, TJ106, TJ108, TJ109, and TJ111) target combinations such as FRα/CDH6, HER2/HER2, EGFR/HER3, EGFR/MET, and Trop2/Nectin4, covering cancer types like ovarian, breast, urothelial, and non-small cell lung cancer. Their proprietary SynTume 2×2 technology underlies this work, offering a modular design for ADC construction.
